Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors

@inproceedings{Chia2014PrevalenceAN,
  title={Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors},
  author={Puey Ling Chia and Paul L. R. Mitchell and Alexander Dobrovic and Thomas Libby John},
  booktitle={Clinical epidemiology},
  year={2014}
}
Improved understanding of molecular drivers of carcinogenesis has led to significant progress in the management of lung cancer. Patients with non-small-cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) gene rearrangements constitute about 4%-5% of all NSCLC patients. ALK+ NSCLC cells respond well to small molecule ALK inhibitors such as crizotinib; however, resistance invariably develops after several months of treatment. There are now several newer ALK inhibitors, with the next… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 102 references

IASLC Atlas of ALK Testing in Lung Cancer. Aurora

  • M-S Tsao, FR Hirsch, Y. Yatabe
  • CO, USA: IASLC;
  • 2013
Highly Influential
9 Excerpts

Clinical trials of MPDL3280A (anti-PDL1) in patients (pts) with non-small cell lung cancer (NSCLC)

  • NA Rizvi, LQM Chow, LY Dirix
  • J Clin Oncol. 2014;32:5s[Suppl; Abstract TPS8123]
  • 2014

Similar Papers

Loading similar papers…